Stockscreener 앱 받기
89.23
1.86%
1.63
시간 외 거래:
89.06
-0.17
-0.19%
Merck Co Inc 주식(MRK)의 최신 뉴스
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING INVESTOR COUNSEL, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - GlobeNewswire
MRK Investors Have Opportunity to Lead the Merck Securities Fraud Lawsuit with Faruqi & Faruqi, LLP - Markets Insider
Why Merck & Co. Inc. (MRK) Went Up On Friday? - Yahoo Finance
Merck Gets Closer To Extending Keytruda Franchise With Subcutaneous Version - Citeline
Levi & Korsinsky Reminds Merck & Co., Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 14, 2025MRK - ACCESS Newswire
Merck Stock Just Reminded Us Why ‘Buy The Dip’ Is Not That Simple - Barchart
FDA Accepts Merck's Filing for Subcutaneous Version of Keytruda - TradingView
MRK SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck plans to launch US subcutaneous version of Keytruda on October 1 - Reuters.com
Merck & Co., Inc. Investors: Please contact the Portnoy Law - GlobeNewswire
Merck & Co., Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. April 14, 2025 Deadline to file Lead Plaintiff Motion. - TradingView
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Merck & Co., Inc. (MRK) Shareholders - ACCESS Newswire
Is Merck & Co. (MRK) the Low Volatility Stock to Buy According to Billionaire Ken Fisher? - Insider Monkey
Investors who lost money on Merck & Co., Inc. (MRK) should contact Levi & Korsinsky ... - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel - Bluefield Daily Telegraph
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Merck & Co., Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – MRK - TradingView
Merck Says Subcutaneous Pembrolizumab Met Primary Endpoints in Phase 3 Trial - Marketscreener.com
Merck Says FDA PDUFA Date For Subcutaneous Pembrolizumab Set For Sept 23 - Marketscreener.com
Why Pfizer Is My Largest Healthcare Position - The Motley Fool
Is Merck & Co., Inc. (MRK) the Best Consistent Dividend Stock to Buy? - Insider Monkey
Jim Cramer on Merck (MRK): “I Like It at This Level – But I Like Bristol-Myers Even More!” - Yahoo Finance
Merck & Co.: Looming Patent Expiries For Key Drugs Weaken Longer-Term Outlook - Seeking Alpha
Merck wins European Commission approval for pneumonia vaccine Capvaxive - Seeking Alpha
Merck & Co. (MRK) Stock: Pharmaceutical Giant Signs $2 Billion Heart Disease Drug Deal - MoneyCheck
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming Deadlines – MRK - TradingView
European Commission (EC) Approves Merck's CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) - Marketscreener.com
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck Receives European Approval for Streptococcal Pneumonia Vaccine - Marketscreener.com
Merck Gets European Commission Approval of Capvaxive Vaccine - Marketscreener.com
Why Merck & Co. Inc. (MRK) Performed Worst On Tuesday? - Insider Monkey
GME, KBSX, MRK, UPS, TSLA: Top 5 Trending Stocks TodayGameStop (NYSE:GME) - Benzinga
Merck Doubles Down On Oral Lipid-Lowering Drugs With Hengrui’s Lp(a) Asset - News & Insights
Is Merck & Co. Inc. (MRK) The Best Defensive Stock Amid Market Volatility? - Insider Monkey
Merck Makes Bold $2B Bet on Chinese Cardio Drug - USA Herald
Merck & Co. Inc. stock underperforms Tuesday when compared to competitors - MSN
For nearly $2B, Jiangsu Hengrui licenses heart drug to Merck - BioWorld Online
Merck Betting Up To $2B On China-Developed Cardio Drug - Law360
Merck & Co Inc (MRK) Trading Down 3.66% on Mar 25 - GuruFocus.com
Merck Partners With Hengrui Pharma In $1.77 Billion Deal For Cardiovascular Treatment - Benzinga
Merck Strikes Nearly $2 Billion Licensing Deal For Chinese Firm's Heart Disease Drug Candidate - Marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Merck & Co., Inc. of Class Action Lawsuit and Upcoming DeadlinesMRK - PR Newswire
MRK Investors Have Final Opportunity to Lead Merck & Co., Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
MRK INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Merck & Co., Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - Markets Insider
Merck inks a licensing deal worth nearly $2B with China’s Jiangsu Hengrui - Seeking Alpha
Merck Will Pay Up to $2 Billion for Chinese Heart Drug Rights - Bloomberg
Is Weakness In Merck & Co., Inc. (NYSE:MRK) Stock A Sign That The Market Could be Wrong Given Its Strong Financial Prospects? - Yahoo Finance
Merck buys rights to heart disease drug in latest China deal - Marketscreener.com
Merck signs deal with Jiangsu Hengrui worth up to $2 billion for access to heart drug - Marketscreener.com
Merck Enters Exclusive License Agreement For HRS-5346 From Jiangsu Hengrui Pharmaceuticals - Marketscreener.com
Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd. - Business Wire
Lost Money on Merck & Co., Inc.(MRK)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - ACCESS Newswire
Merck & Co. sees ratings upgrade to Aa3 by Moody’s Ratings - Investing.com
Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc. (Fed. Cir. 2025) - JD Supra
ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Merck & Co. - Business Wire
1.05%
1.23%
자본화:
|
볼륨(24시간):